person · Reporting owner
MILLER MICHAEL PATRICK
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director | January 09, 2026 | January 13, 2026 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | EVP, US Commercial | March 12, 2020 | March 13, 2020 |
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | Director | June 11, 2026 | June 16, 2026 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | May 15, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioXcel Therapeutics, Inc.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-09 | Direct | 17,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 17,000 · Balance 17,000 F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.
Jazz Pharmaceuticals plc
Report date March 12, 2020 · Filed March 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 22,118 |
Reported balance
After 2020-03-12 transaction · row 1
1 source rowRow 1 · 2020-03-12 · Sale · Disposed 1,500 · Balance 22,118 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
PUMA BIOTECHNOLOGY, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,000 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 27,000 · Balance 81,000 F1: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.
RIGEL PHARMACEUTICALS INC
Report date May 15, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,937 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 5,750 · Balance 5,937 F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 16, 2026 00:12 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-020705 · rdgdoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,000 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 15, 2026 Filed May 20, 2026 00:49 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002533 · form4.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,937 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:09 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $34.86 | $0.00 |
DisclosureSEC source: 0000905148-26-000482 · form4.xml · derivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-02-01 F1 · derivative.exercise_date: The option shall vest in equal monthly installments over a period beginning on February 1, 2026 and ending on the date of the annual meeting at which the Reporting Person is first scheduled to be considered for election by the stockholders, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 00:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001104659-26-002976 · tm262917-3_4seq1.xml · derivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2036-01-09 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:41 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 20,000 | $4.86 | $97,228.00 |
DisclosureSEC source: 0001437749-25-034874 · rdgdoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.82 to $4.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 11, 2025 Filed Jun 14, 2025 00:19 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-020363 · rdgdoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 01:09 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 23,358 | $3.49 | $81,465.70 |
DisclosureSEC source: 0001437749-24-026536 · rdgdoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.4201 to $3.5501, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Corrects the amount that was erroneously reported as held in the Form 4 filed on June 21, 2024 with the Securities and Exchange Commission. Read SEC document |
| June 18, 2024 Filed Jun 22, 2024 01:21 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-021018 · rdgdoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,358 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001104659-24-070515 · tm2416928-2_4seq1.xml · derivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2034-06-10 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 21:19 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 25,000 | $2.83 | $70,802.50 |
DisclosureSEC source: 0001437749-23-031275 · rdgdoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,358 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.7801 to $2.8801, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 20:59 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0001104659-23-075868 · tm2319786-2_4seq1.xml · derivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-26 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 00:28 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-017594 · rdgdoc.xml · nonDerivative · entry 2 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,358 F3 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 00:28 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 13,500 | $3.45 | $46,630.35 |
DisclosureSEC source: 0001437749-23-017594 · rdgdoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,358 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-14-2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.43 to $3.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 22:01 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 25,000 | $3.55 | $88,792.50 |
DisclosureSEC source: 0001437749-22-019857 · rdgdoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,858 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.4828 to $3.6700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 01:04 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.27 | $0.00 |
DisclosureSEC source: 0001104659-22-077473 · tm2220442-1_4seq1.xml · derivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-07-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in three substantially equal annual installments following the date of grant, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:56 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-015212 · rdgdoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,858 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 20:33 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 25,653 | $2.80 | $71,792.49 |
DisclosureSEC source: 0001437749-22-006597 · rdgdoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,858 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.78 to $2.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:38 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 27,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041731 · doc4.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,511 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 09, 2020 Filed Jun 12, 2020 00:04 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 25,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036122 · doc4.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,653 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 22:46 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,500 | $102.17 | $153,255.00 |
DisclosureSEC source: 0001765581-20-000045 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,118 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 23:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 2,423 | $124.50 | $301,663.50 |
DisclosureSEC source: 0001765581-20-000034 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,618 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 22:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 530 | $127.25 | $67,442.50 |
DisclosureSEC source: 0001765581-20-000012 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,041 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 22:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,500 | $142.18 | $213,270.00 |
DisclosureSEC source: 0001765581-20-000010 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,571 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:11 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,500 | $146.78 | $220,170.00 |
DisclosureSEC source: 0001765581-20-000006 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,071 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 23:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,500 | $149.12 | $223,680.00 |
DisclosureSEC source: 0001765581-19-000102 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,571 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 32 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 29, 2019. Read SEC document |
| June 10, 2019 Filed Jun 13, 2019 00:37 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 19,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036572 · doc4.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,905 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:46 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 123 | $130.40 | $16,039.20 |
DisclosureSEC source: 0001765581-19-000049 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,039 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 140 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2019. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 00:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 648 | $135.82 | $88,011.36 |
DisclosureSEC source: 0001765581-19-000037 · edgardoc.xml · nonDerivative · entry 2 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,022 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 00:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 833 | $135.82 | $113,138.06 |
DisclosureSEC source: 0001765581-19-000037 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,670 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:36 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,286 | $0.00 Strike: $140.03 | $0.00 |
DisclosureSEC source: 0001765581-19-000021 · edgardoc.xml · derivative · entry 3 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,286 Underlying: Ordinary Shares · 20,286 shares Expires 2029-02-27 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:36 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 714 | $0.00 Strike: $140.03 | $0.00 |
DisclosureSEC source: 0001765581-19-000021 · edgardoc.xml · derivative · entry 2 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714 Underlying: Ordinary Shares · 714 shares Expires 2029-02-27 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:36 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 8,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-19-000021 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,503 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 23:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 414 | $127.76 | $52,892.64 |
DisclosureSEC source: 0001765581-19-000008 · edgardoc.xml · nonDerivative · entry 2 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,103 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:38 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 528 | $126.25 | $66,660.00 |
DisclosureSEC source: 0001765581-19-000008 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,517 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 73 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2018. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 01:08 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $149.27 | $29,854.00 |
DisclosureSEC source: 0001232524-18-000194 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,972 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 20:28 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $158.46 | $31,692.00 |
DisclosureSEC source: 0001232524-18-000178 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,172 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $165.20 | $33,040.00 |
DisclosureSEC source: 0001232524-18-000169 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:52 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $175.70 | $35,140.00 |
DisclosureSEC source: 0001232524-18-000162 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,572 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 20:44 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $179.15 | $35,830.00 |
DisclosureSEC source: 0001232524-18-000119 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,772 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:37 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $176.53 | $35,306.00 |
DisclosureSEC source: 0001232524-18-000113 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,972 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 22:36 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 5,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-037867 · doc4.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,482 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:42 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 123 | $172.54 | $21,222.42 |
DisclosureSEC source: 0001232524-18-000111 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,172 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 173 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2018. Read SEC document |
| May 14, 2018 Filed May 15, 2018 21:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $164.68 | $32,936.00 |
DisclosureSEC source: 0001232524-18-000101 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,122 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:22 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,159 | $147.03 | $170,407.77 |
DisclosureSEC source: 0001232524-18-000096 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,322 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| April 13, 2018 Filed Apr 13, 2018 21:22 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $157.49 | $31,498.00 |
DisclosureSEC source: 0001232524-18-000078 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,481 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 21:10 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $151.12 | $30,224.00 |
DisclosureSEC source: 0001232524-18-000070 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,681 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:11 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 648 | $143.39 | $92,916.72 |
DisclosureSEC source: 0001232524-18-000063 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,881 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:30 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,290 | $0.00 Strike: $140.67 | $0.00 |
DisclosureSEC source: 0001232524-18-000045 · edgardoc.xml · derivative · entry 3 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,290 Underlying: Ordinary Shares · 19,290 shares Expires 2028-02-29 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:30 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 710 | $0.00 Strike: $140.67 | $0.00 |
DisclosureSEC source: 0001232524-18-000045 · edgardoc.xml · derivative · entry 2 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710 Underlying: Ordinary Shares · 710 shares Expires 2028-02-29 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:30 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-18-000045 · edgardoc.xml · nonDerivative · entry 1 MILLER MICHAEL PATRICK · CIK 0001236514 · EVP, US Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,529 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2018, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.